Possibilities of using memantine in early therapy of post-stroke dementia
Chimagomedova A.Sh.¹, Levin O.S.¹, Skripkina N.A.¹, Gutorova D.A.^1,2, Vasenina E.Е.<sup>1

1</sup> Russian Medical Academy of Сontinuous Professional Education, Moscow
² «The Hospital of Veterans of Wars No. 1» of the City Health Department of Moscow

Cognitive disorders that occur in a significant number of patients after a stroke, affect the household, social and professional adaptation. Post-stroke cognitive impairment (PSCI) of different severity is detected in 20-70% of stroke patients, on average in about half of patients. The risk of PSCI development depends on various factors: age, the state of cognitive functions prior to stroke, arterial hypertension, diabetes mellitus, heart pathology, etc. An important direction in improving the prognosis is the timely treatment of cognitive disorders, but it remains unclear how long the drugs should be used. A number of studies demonstrate the neuroprotective effect of a non-selective blocker of glutamatergic NMDA receptors of memantine in ischemic brain damage. The article presents a review of the studies confirming its efficacy both in patients with vascular dementia and in the acute stage of stroke, which makes it possible to use memantine as an early therapy for cognitive impairment and to prevent complications of thrombolytic therapy.

Key words: post-stroke cognitive impairment, vascular dementia, stroke, memantine.
For citation: Chimagomedova A.Sh., Levin O.S., Skripkina N.A. et al. Possibilities of using memantine in early therapy of post-stroke dementia // RMJ. 2017. № 21. P. 1512–1517.